Lactoferrin inhibits the growth of nasal polyp fibroblasts

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1139-1147

  Nadolska, Beata ^a   Fra̧czek, Marcin ^a   Krȩcicki, Tomasz ^a   Kociȩba, Maja ^b   Zimecki, Michał ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Fibroblasts; Heparan sulfate; Lactoferrin; Nasal polyps

Indexed keywords

CELL RECEPTOR; GLYCAN; HEPARIN; LACTOFERRIN; PROTEOHEPARAN SULFATE; SODIUM CHLORATE; SUGAR;

ANIMAL EXPERIMENT; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG BINDING; DRUG EFFECT; FIBROBLAST CULTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; NOSE POLYP;

EID: 79551500050     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70376-5     Document Type: Article

References (49)

1. Artym J, Zimecki MP: The effect of lactoferrin on myelopoiesis: Can we resolve the controversy? Post Hig Med Dosw, 2007, 61, 129-150.
2. Artym J, Zimecki M, Kruzel M: Normalization of peripheral blood cell composition by lactoferrin in cyclophosphamide-treated mice. Med Sci Monit, 2004, 10, BR84-89.
3. Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P: Nasal polyposis: from cytokines to growth. Am J Rhinol, 2000, 14, 279-290.
4. Baveye S, Elass E, Mazurier J, Spik G, Legrand D: Lactoferrin: a multifunctional protein involved in the modulation of the inflammatory process. Clin Chem Lab Med, 1999, 37, 281-286.
5. Bernstein JM: Update on the molecular biology of nasal polyposis. Otolaryngol Clin North Am, 2005, 38, 1243-1255.
6. Bezwoda WR, Mansoor N: Lactoferrin from human breast milk and from neutrophil granulocytes. Comparative studies of isolation, quantitation, characterization and iron binding properties. Biomed Chromatogr, 1989, 3, 121-126.
7. Bhandari A, Takeuchi K, Suzuki S, Harada T, Hayashi S, Imanaka-Yoshida K, Yoshida T, Majima Y: Increased expression of matrix metalloproteinase-2 in nasal polyps. Acta Otolaryngol, 2004, 124, 1165-1170. (Pubitemid 40051567)
8. Bhimani RS, Vendrow Y, Furmanski P: Influence of lactoferrin feeding and injection against systemic staphylococcal infections in mice. J Appl Microb, 1999, 86, 135-144.
9. Bournazou I, Mackenzie KJ, Duffin R, Rossi AG, Gregory CD: Inhibition of eosinophil migration by lactoferrin. Immunol Cell Biol, 2010, 88, 220-223.
10. Choi B-K, Actor JK, Rion S, d'Anjon M, Stadheim TA, Warbuton S, Giacone E et al.: Effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response. Glycoconjugate J, 2008, 25, 581-593.
11. Curran Cs, Demick KP, Mansfield JM: Lactoferrin activates macrophages via TLR-4-dependent and-independent signaling pathways. Cell Immunol, 2006, 242, 23-30.
12. Damiens E, El Yazidi I, Mazurier J, Duthille I, Spik G, Boilly-Marer Y: Lactoferrin inhibits G1 cyclin-dependent kinase during growth arrest of human breast carcinoma cells. J Cell Biochem, 1999, 74, 486-498.
13. Elass-Rochard E, Legrand D, Salmon V, Roseanu A, Trif M, Tobias PS, Mazurier J, Spik G: Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun, 1998, 66, 486-491.
14. Fannon M, Forsten KE, Nugent MA: Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. Biochemistry, 2000, 39, 1434-1445.
15. Guttenberg TJ, Rokke O, Andersen O, Jorgensen T: Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: an early defense mechanism. Scand J Infect Dis, 1989, 21, 709-715.
16. Hansen MB, Nielsen SE, Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/kill. J Immunol Methods, 1989, 119, 203-210.
17. Hwang SA, Wilk K, Kruzel ML, Actor JK: A novel human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice. Vaccine, 2009, 27, 3026-3034.
18. Kozu T, Iinuma G, Ohashi Y, Saito Y, Akasu T, Saito D, Alexander DB et al.: Effect of orally administered bovine lactoferrin on the growth of adenomatous colectoral polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res (Phila), 2009, 2, 975-983.
19. Kruzel ML, Bacsi A, Choudhury B, Sur S, Boldogh I: Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. Immunology, 2006, 119, 159-166.
20. Kruzel ML, Harari Y, Chen CY, Castro GA: The gut. A key metabolic organ protected by lactoferrin during experimental systemic inflammation in mice. Adv Exp Med Biol, 1998, 443, 167-173.
21. Lanza DC, Kennedy DW: Adult rhinosinusitis defined. Otolaryngol Head Neck Surg, 1997, 117, 1-7.
22. Lee SH, Park SW, Pyo CW, Yoo NK, Kim J, Choi SY: Requirement of the JNK-associated Bcl-2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. Biochimie, 2009, 91, 102-108.
23. Liu Z, Kim J, Sypek JP, Wang IM, Horton H, Oppenheim FG, Bochner BS: Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray. J Allergy Clin Immunol, 2004, 114, 783-790.
24. Lonnerdal B, Iyer S: Lactoferrin: molecular structure and biological function. Annu Rev Nutr, 1995, 15, 93-110.
25. Mann DM, Romm E, Migliorini M: Delineation of the glycosaminoglycan- binding site in the human inflammatory response protein lactoferrin. J Biol Chem, 1994, 269, 23661-23667.
26. Newsome AL, Johnson JP, Seipelt TL, Thompson MW: Apolactoferrin inhibits the catalytic domain of matrix metalloproteinase-2 by zinc chelation. Biochem Cell Biol, 2007, 85, 563-572.
27. Nonaka M, Fukumoto A, Ogihara N, Pawankar R, Sakanushi A, Yagi T: Expression of MCP-4 by TLR ligand-stimulated nasal polyp fibroblasts. Acta Otolaryngol, 2007, 127, 1304-1309.
28. Ogra PL: Developmental aspects of the mucosal immune system: role of external environment, mucosal microflora and milk. Adv Exp Med Biol, 2009, 639, 41-56.
29. Pawankar R: Nasal polyps: an update: editorial review. Curr Opin Allergy Clin Immunol, 2003, 3, 1-6.
30. Psaltis AJ, Wormald PJ, Ha KR, Tan LW: Reduced levels of lactoferrin in biofilm -associated chronic rhinosinusitis. Laryngoscope, 2008, 118, 895-901.
31. Psaltis AJ, Bruhn MA, Ooi EH, Tan LW, Wormald PJ: Nasal mucosa expression of lactoferrin in patients with chronic rhinosinusitis. Laryngoscope, 2007, 117, 2030-2035.
32. Raphael GD, Igarashi Y, White MW, Kaliner MA: The pathophysiology of rhinitis. V. Sources of protein in allergen-induced nasal secretions. J Allergy Clin Immunol, 1991, 88, 33-42.
33. Raphael GD, Jeney EV, Baraniuk JN, Kim I, Meredith SD, Kaliner MA: Pathophysiology of rhinitis. Lactoferrin and lysozyme in nasal secretions. J Clin Invest, 1989, 84, 1528-1535.
34. Riechelmann H, Deutschle T, Friemel E, Gross H-J, Bachem M: Biological markers in nasal secretions. Eur Respir J, 2003, 21, 600-605.
35. Rinia AB, Kostamo K, Ebbens FA, van Drunen CM, Fokkens WJ: Nasal polyposis: a cellular-based approach to answering questions. Allergy, 2007, 62, 348-358.
36. Sato R, Inanami O, Tanaka Y, Takese M, Naito Y: Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am J Vet Res, 1996, 57, 1443-1446.
37. Soares RV, Lin T, Siqueira CC, Bruno LS, Li X, Oppenheim FG, Offner G, Troxler RF: Salivary micelles: identification of complexes containing MG2, sIgA, lactoferrin, amylase, glycosylated proline-rich protein and lysozyme. Arch Oral Biol, 2004, 49, 337-343.
38. Suzuki YA, Lopez V, Lonnerdal B: Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci, 2005, 62, 2560-2575.
39. Uchida J, Kanai K, Asano K, Watanabe S, Hisamitsu T, Suzaki H: Influence of fluticasone propionate on the production of vascular endothelial factor and basic fibroblast growth factor from nasal fibroblasts in vitro. In Vivo, 2004, 18, 767-770.
40. Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H: Cooperative anti-candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol Immunol, 1996, 40, 821-825.
41. Watanabe K, Shirasaki H, Kanaizumi E, Himi T: Effects of glucocorticoids on infiltrating cells and epithelial cells of nasal polyps. Ann Otol Rhinol Laryngol, 2004, 113, 465-473.
42. Yi HM, Li H, Peng D, Zhang HJ, Wang L, Zhao M, Ya KT, Ren CP: Genetic and epigenetic alterations of LFT at 3p21.3 in nasopharyngeal carcinoma. Oncol Res, 2006, 16, 261-272.
43. Zhang L, Han D, Wang Z: Lysozyme and lactoferrin in human uncinate process mucosa during chronic sinusitis. Zhonghua Er Bi Yan Hou Ke Za Zhi, 1998, 33, 219-221.
44. Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, Tan Y, Yi Wet al.: Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of NCP cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer, 2008, 123, 2065-2072.
45. Zimecki M, Kocieba M, Kruzel M: Immunoregulatory activities of lactoferrin in the delayed type hypersensitivity in mice are mediated by a receptor with affinity to mannose. Immunobiology, 2002, 205, 120-131.
46. Zimecki M, Kruzel M: Milk derived proteins and peptides of potential therapeutic and nutritive value. J Exp Ther Oncol, 2007, 6, 89-106.
47. Zimecki M, Mazurier J, Machnicki M, Wieczorek Z, Montreuil J, Spik G: Immunostimulatory activity of lactotransferrin and maturation of CD4-CD8- murine thymocytes. Immunol Lett, 1991, 30, 119-123.
48. Zimecki M, Mazurier J, Spik G, Kapp JA: Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology, 1995, 86, 122-127.
49. Zimecki M, Stepniak D, Szynol A, Kruzel ML: Lactoferrin regulates proliferative response of human peripheral blood mononuclear cells to phytohemagglutinin and mixed lymphocyte reaction. Arch Immunol Ther Exp, 2001, 49, 147-154.